Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

Contributed by: PR Newswire

Tags

H.-Lundbeck-A/S

More Like This

Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention

Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine

Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference

Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting

Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine